Obesity-related colon cancer: Dietary factors and their mechanisms of anticancer action

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 2, 2012, Pages 161-167

  Zeng, Huawei ^a   Lazarova, Darina L ^b  

^a GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

^b Janet Weis Children s Hospital   (United States)

Author keywords

Colon cancer; Dietary factor; Inflammation; Insulin resistance; Obesity

Indexed keywords

ADIPONECTIN; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CARBOHYDRATE; CYCLOOXYGENASE 2; ENVIRONMENTAL MUTAGEN; FOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; OMEGA 3 FATTY ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYPHENOL; REACTIVE OXYGEN METABOLITE; RESISTIN; SELENIUM; SOMATOMEDIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; VITAMIN D;

ADIPOSE TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALORIC INTAKE; CANCER PREVENTION; CANCER RISK; COLON CANCER; COLON CARCINOGENESIS; CYTOKINE PRODUCTION; DIETARY FIBER; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DNA REPAIR; DNA SYNTHESIS; ENERGY EXPENDITURE; GENETIC PREDISPOSITION; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; MACROPHAGE; OBESITY; OXIDATIVE STRESS; PHYTOCHEMISTRY; RISK ASSESSMENT; RISK REDUCTION; TEA; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; COLONIC NEOPLASMS; DIET; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MICRONUTRIENTS; OBESITY; OVERWEIGHT; RISK FACTORS;

EID: 84856426334     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05518.x     Document Type: Article

References (75)

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
2. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 2009; 18: 2569-78.
3. Pischon T, Nöthlings U, Boeing H. Obesity and cancer. Proc. Nutr. Soc. 2008; 67: 128-45.
4. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer. Epidemiology, mechanisms and candidate genes. J. Nutr. Biochem. 2006; 17: 145-56.
5. Birmingham JM, Busik JV, Hansen-Smith FM, Fenton JI. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis 2009; 30: 690-7.
6. Murthy NS, Mukherjee S, Ray G, Ray A. Dietary factors and cancer chemoprevention. An overview of obesity-related malignancies. J. Postgrad. Med. 2009; 55: 45-54.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Fearon ER Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011; 6: 479-507.
9. Hursting SD, Lashinger LM, Wheatley KWet al.Reducing the weight of cancer: Mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract. Res. Clin. Endocrinol. Metab. 2008; 22: 659-69.
10. Renehan AG, Roberts DL, Dive C. Obesity and cancer. Pathophysiological and biological mechanisms. Arch. Physiol. Biochem. 2008; 114: 71-83.
11. Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes. Rev. 2009; 10: 610-16.
12. Irigaray P, Newby JA, Lacomme S, Belpomme D. Overweight/obesity and cancer genesis: More than a biological link. Biomed. Pharmacother. 2007; 61: 665-78.
13. Atkinson RL Could viruses contribute to the worldwide epidemic of obesity?Int. J. Pediatr. Obes. 2008; 3(Suppl. 1): 37-43.
14. Rondinone CM Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 81-90.
15. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res. 2003; 11: 525-31.
16. Ramos EJ, Xu Y, Romanova Iet al.Is obesity an inflammatory disease?Surgery 2003; 134: 329-35.
17. Draper HH, Bettger WJ. Role of nutrients in the cause and prevention of oxygen radical pathology. Adv. Exp. Med. Biol. 1994; 366: 269-89.
18. Dandona P, Thusu K, Cook Set al.Oxidative damage to DNA in diabetes mellitus. Lancet 1996; 347: 444-5.
19. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14.
20. Munkholm P Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2003; 18(Suppl. 2): 1-5.
21. Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit. Rev. Oncol. Hematol. 2004; 52: 81-101.
22. Gunter MJ, Stolzenberg-Solomon R, Cross AJet al.A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006; 66: 2483-7.
23. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: A link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2004; 13: 279-84.
24. Deng L, Zhou JF, Sellers RSet al.A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am. J. Pathol. 2010; 176: 952-67.
25. John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA. Systematic review: Adipose tissue, obesity and gastrointestinal diseases. Aliment. Pharmacol. Ther. 2006; 23: 1511-23.
26. Johnson IT, Lund EK. Review article: Nutrition, obesity and colorectal cancer. Aliment. Pharmacol. Ther. 2007; 26: 161-81.
27. Kaler P, Godasi BN, Augenlicht L, Klampfer L. The NF-kappaB/AKT-dependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1beta. Cancer Microenviron. 2009; 2: 69-80.
28. Blumenthal A, Ehlers S, Lauber Jet al.The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006; 108: 965-73.
29. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 504-10.
30. Hillon P, Guiu B, Vincent J, Petit JM. Obesity, Type 2 diabetes and risk of digestive cancer. Gastroenterol. Clin. Biol. 2010; 34: 529-33.
31. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004; 4: 505-18.
32. Tentori L, Graziani G. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: Is there a cancer risk?Pharmacol. Res. 2007; 55: 359-69.
33. Calle EE, Kaaks R. Overweight, obesity and cancer. Epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004; 4: 579-91.
34. Tran TT, Naigamwalla D, Oprescu AIet al.Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 2006; 147: 1830-7.
35. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 1995; 95: 1897-905.
36. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 1013-15.
37. Jenkins PJ, Fairclough PD, Richards Tet al.Acromegaly, colonic polyps and carcinoma. Clin. Endocrinol. 1997; 47: 17-22.
38. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 2000; 11: 579-88.
39. Kim YS, Milner JA. Dietary modulation of colon cancer risk. J. Nutr. 2007; 137(Suppl.): S2576-9.
40. Zeng H Selenium as an essential micronutrient. Roles in cell cycle and apoptosis. Molecules 2009; 14: 1263-78.
41. Nelson MA, Goulet AC, Jacobs ET, Lance P. Studies into the anticancer effects of selenomethionine against human colon cancer. Ann. NY Acad. Sci. 2005; 1059: 26-32.
42. Cheng WH Impact of inorganic nutrients on maintenance of genomic stability. Environ. Mol. Mutagen. 2009; 50: 349-60.
43. Duntas LH Selenium and inflammation: Underlying anti-inflammatory mechanisms. Horm. Metab. Res. 2009; 41: 443-7.
44. Qi Y, Schoene NW, Lartey FM, Cheng WH. Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells. J. Biol. Chem. 2010; 285: 33010-17.
45. Jackson MI, Combs GFJr. Selenium and anticarcinogenesis: Underlying mechanisms. Curr. Opin. Clin. Nutr. Metab. Care 2008; 11: 718-26.
46. Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN. Calcium, vitamin D, and dairy product intake and prostate cancer risk: The Multiethnic Cohort Study. Am. J. Epidemiol. 2007; 166: 1259-69.
47. McCullough ML, Robertson AS, Rodriguez Cet al.Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 2003; 14: 1-12.
48. MacLeod RJ, Hayes M, Pacheco I. Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 293: G403-11.
49. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: Molecular mechanisms. Nat. Rev. Cancer 2003; 3: 601-14.
50. 3. Oncogene 2009; 28: 3892-902.
51. Peterlik M, Grant WB, Cross HS. Calcium, vitamin D and cancer. Anticancer Res. 2009; 29: 3687-98.
52. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH, Lipkin M. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: A preclinical model for human sporadic colon cancer. Carcinogenesis 2009; 30: 88-92.
53. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 2000; 72: 690-3.
54. Giovannucci E Epidemiologic studies of folate and colorectal neoplasia: A review. J. Nutr. 2002; 132(Suppl.): S2350-5.
55. Duthie SJ Folate and cancer. How DNA damage, repair and methylation impact on colon carcinogenesis. J. Inherit. Metab. Dis. 2011; 34: 101-9.
56. Buettner R, Bettermann I, Hechtl Cet al.Dietary folic acid activates AMPK and improves insulin resistance and hepatic inflammation in dietary rodent models of the metabolic syndrome. Horm. Metab. Res. 2010; 42: 769-74.
57. Milagro FI, Campión J, García-Díaz DF, Goyenechea E, Paternain L, Martínez JA. High fat diet-induced obesity modifies the methylation pattern of leptin promoter in rats. J. Physiol. Biochem. 2009; 65: 1-9.
58. Fujiki K, Kano F, Shiota K, Murata M. Expression of the peroxisome proliferator activated receptor gamma gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes. BMC Biol. 2009; 7: 38.
59. Lupton JR Microbial degradation products influence colon cancer risk: The butyrate controversy. J. Nutr. 2004; 134: 479-82.
60. Galvez J, Rodríguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol. Nutr. Food Res. 2005; 49: 601-8.
61. Augenlicht LH, Mariadason JM, Wilson Aet al.Short chain fatty acids and colon cancer. J. Nutr. 2002; 132(Suppl.): S3804-8.
62. Zeng H, Briske-Anderson M. Prolonged butyrate treatment inhibits the migration and invasion potential of HT1080 tumor cells. J. Nutr. 2005; 135: 291-5.
63. Bordonaro M, Lazarova DL, Sartorelli AC. Butyrate and Wnt signaling: A possible solution to the puzzle of dietary fiber and colon cancer risk?Cell Cycle 2008; 7: 1178-83.
64. Bordonaro M, Lazarova DL, Sartorelli AC. Hyperinduction of Wnt activity: A new paradigm for the treatment of colorectal cancer?Oncol. Res. 2008; 17: 1-9.
65. Roynette CE, Calder PC, Dupertuis YM, Pichard C. n-3 polyunsaturated fatty acids and colon cancer prevention. Clin. Nutr. 2004; 23: 139-51.
66. Caygill CP, Hill MJ. Fish, n-3 fatty acids and human colorectal and breast cancer mortality. Eur. J. Cancer Prev. 1995; 4: 329-32.
67. Calviello G, Serini S, Piccioni E. n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: Molecular mechanisms involved. Curr. Med. Chem. 2007; 14: 3059-69.
68. Calviello G, Di Nicuolo F, Gragnoli Set al.n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 2004; 25: 2303-10.
69. Vanamala J, Tarver CC, Murano PS. Obesity-enhanced colon cancer. Functional food compounds and their mechanisms of action. Curr. Cancer Drug Targets 2008; 8: 611-33.
70. Johnson IT, Williamson G, Musk SR. Anticarcinogenic factors in plant foods: A new class of nutrients?Nutr. Res. Rev. 1994; 7: 175-204.
71. Liu RH Potential synergy of phytochemicals in cancer prevention: Mechanism of action. J. Nutr. 2004; 134(Suppl.): S3479-85.
72. de Kok TM, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds: A review. Eur. J. Nutr. 2008; 47(Suppl. 2): 51-9.
73. Gorelik S, Lapidot T, Shaham Iet al.Lipid peroxidation and coupled vitamin oxidation in simulated and human gastric fluid inhibited by dietary polyphenols: Health implications. J. Agric. Food. Chem. 2005; 53: 3397-402.
74. Horie N, Hirabayashi N, Takahashi Y, Miyauchi Y, Taguchi H, Takeishi K. Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells. Biol. Pharm. Bull. 2005; 28: 574-9.
75. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H. Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res. 1999; 59: 44-7.